AstraZeneca, Sun Dismiss Patent Suits Over Three Diabetes Drugs

AstraZeneca Plc and Sun Pharmaceutical Industries Ltd. agreed to end three lawsuits alleging Sun’s proposed copies of AstraZeneca’s Farxiga, Qtern, and Xigduo XR diabetes treatments infringe a patent that expired last week.

Both sides agreed to dismiss all claims and defenses in each lawsuit, though they left the door open for renewing allegations, according to the three orders Judge Richard G. Andrews issued Wednesday in the US District Court for the District of Delaware.

Each of the complaints AstraZeneca filed in December 2023 alleged the targeted generic drug infringed US Patent No. 6,515,117, which covers the compound dapagliflozin, its ...